Chemoinformaics analysis of (1R,2S,5S)-2,6,6-TRIMETHYLBICYCLO[3.1.1]HEPTAN-2-OL
| Molecular Weight | 154.253 | nRot | 0 |
| Heavy Atom Molecular Weight | 136.109 | nRig | 13 |
| Exact Molecular Weight | 154.136 | nRing | 3 |
| Solubility: LogS | -2.852 | nHRing | 0 |
| Solubility: LogP | 1.589 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 3 |
| Atoms Count | 29 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 11 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 2 | No. Saturated Carbocycles | 3 |
| No. of Hydrogen atom | 18 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 3 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 29.5043 |
| nHD | 1 | BPOL | 18.0577 |
| QED | 0.493 |
| Synth | 5.103 |
| Natural Product Likeliness | 3.521 |
| NR-PPAR-gamma | 0.05 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.002 |
| Pgp-sub | 0.001 |
| HIA | 0.01 |
| CACO-2 | -4.534 |
| MDCK | 0.0000053 |
| BBB | 0.292 |
| PPB | 0.56131 |
| VDSS | 1.205 |
| FU | 0.39261 |
| CYP1A2-inh | 0.013 |
| CYP1A2-sub | 0.111 |
| CYP2c19-inh | 0.011 |
| CYP2c19-sub | 0.323 |
| CYP2c9-inh | 0.004 |
| CYP2c9-sub | 0.054 |
| CYP2d6-inh | 0.059 |
| CYP2d6-sub | 0.067 |
| CYP3a4-inh | 0.851 |
| CYP3a4-sub | 0.164 |
| CL | 5.426 |
| T12 | 0.821 |
| hERG | 0.014 |
| Ames | 0.046 |
| ROA | 0.035 |
| SkinSen | 0.794 |
| Carcinogencity | 0.773 |
| EI | 0.76 |
| Respiratory | 0.852 |
| NR-Aromatase | 0.847 |
| Antiviral | No |
| Prediction | 0.934817 |